Hasty approval, more withdrawals.
Two studies have shown that in the 1990s the number of market withdrawals due to adverse effects increased while the time regulatory agencies have taken to approve new drugs decreased. More recent examples confirm that hasty approvals place patients at an increased risk of serious adverse effects.